Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

1075TiP - A phase I trial of ATG-101, an investigational PD-L1×4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN

Date

14 Sep 2024

Session

Poster session 04

Presenters

Junli Xue

Citation

Annals of Oncology (2024) 35 (suppl_2): S674-S711. 10.1016/annonc/annonc1596

Authors

J. Xue1, J. Wen2, J. Xiong3, Y. Sun4, J. Zhao5, Y. Guo6

Author affiliations

  • 1 Department Of Oncology, Shanghai East/Oriental Hospital Affiliated to Tongji University - Southern Division, 200031 - Shanghai/CN
  • 2 Department Of Oncology, The First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
  • 3 Oncology Dept., The First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
  • 4 Department Of Oncology, Shandong Cancer Hospital and Institute, 250117 - Jinan/CN
  • 5 Biostatistics, Antengene Corporation Limited, 200051 - Shanghai/CN
  • 6 Medical Oncology, Shanghai East Hospital, Tongji University, 200123 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1075TiP

Background

ATG-101 is a novel bispecific antibody targeted to PD-L1 and 4-1BB. 4-1BB is an inducible costimulatory receptor expressed on activated T cells and other immune cell populations. The clinical development of 4-1BB agonist monoclonal antibodies has been hampered by limited efficacy and/or toxicity, notably hepatotoxicity. ATG-101 addresses these issues by enhancing the activity of 4-1BB agonism whilst reducing the potential of systemic toxicity through strategic engineering. First, the high affinity PD-L1 binder ensures preferential antibody distribution to the tumor microenvironment. In addition, conditional 4-1BB activation requiring trimer formation, reduces nonspecific activation. Finally, the absence of binding affinity toFcγR further mitigates the risk of effective nonspecific 4-1BB activation. ATG-101 demonstrated potent in vivo anti-tumor activities in various animal models and has been granted Orphan Drug Designation for the treatment of pancreatic cancer by the US FDA, providing rationale for PROBE-CN.

Trial design

PROBE-CN is a phase I, multi-center, open-label study in China to evaluate ATG-101 as a single agent in patients with advanced solid tumors and mature relapsed/refractory (RR) B-NHL. The study includes a dose escalation phase which enrolls patients with advanced solid tumors, and a dose expansion phase which enrolls selected cohorts of patients with advanced solid tumors or RR B-NHL to further evaluate safety and efficacy of ATG-101. The primary objective is to evaluate the safety and to determine MTD/RP2D and/or optimal biological dose of ATG-101. Patients must have advanced disease that has relapsed from or been refractory to standard therapies; measurable lesion per RECIST v1.1; ECOG PS ≤1. The starting dose for escalation is 0.014 mg/kg, and single-patient cohorts have been applied for the first two dose levels, with a BOIN design used in the following cohorts. The patients receive a dose intravenously once every 28 days (1 cycle), and the DLTs will be evaluated during the first cycle. As of 5 January 2024, four clinical sites in China are open to recruitment and 22 patients across eight dose levels have been enrolled.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Antengene (Hangzhou) Biologics Co., Ltd.

Funding

Antengene (Hangzhou) Biologics Co., Ltd.

Disclosure

J. Zhao: Financial Interests, Personal and Institutional, Full or part-time Employment: Antengene. Y. Guo: Financial Interests, Personal, Invited Speaker: Merck Serono, Roche, MSD, BMS, BeiGene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.